Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications

Konen, Franz Felix; Schwenkenbecher, Philipp; Jendretzky, Konstantin Fritz; Gingele, Stefan; Grote-Levi, Lea; Möhn, Nora; Maecker‐Kolhoff, Britta; Trebst, Corinna; Skripuletz, Thomas; Hümmert, Martin W.

doi:10.3390/cells11142165

Cited by 5 publications

(3 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous hematopoietic stem cell transplantation (HSCT) has been employed in cases of refractory NMOSD with varying treatment regimens and results, with some improvement in disease activity and disability reported [ 10 , 34 , 35 , 75 , 115 ]. The inclusion of rituximab in the conditioning regimen before HSCT may improve treatment outcomes.…”

Section: Treatment Of Nmosd: General Aspects and Outcome Measuresmentioning

confidence: 99%

“…Compared to other highly effective approved immunotherapies, HSCT is yet to be studied in randomized, actively controlled trials and—if at all—may be used for individual cases of refractory NMOSD. Other experimental approaches, such as allogeneic HSCT, autologous and allogeneic mesenchymal stem cell transplantation, and peptide-loaded tolerogenic dendritic cell transplantation, have been performed in selected NMOSD patients [ 115 ].…”

Section: Treatment Of Nmosd: General Aspects and Outcome Measuresmentioning

confidence: 99%

See 1 more Smart Citation

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Kuempfel¹,

Giglhuber²,

Aktaş³

et al. 2023

J Neurol

Self Cite

View full text Add to dashboard Cite

This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.

show abstract

Section: Treatment Of Nmosd: General Aspects and Outcome Measuresmentioning

confidence: 99%

Section: Treatment Of Nmosd: General Aspects and Outcome Measuresmentioning

confidence: 99%

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Kuempfel¹,

Giglhuber²,

Aktaş³

et al. 2023

J Neurol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consequently, there is a growing demand for novel adjuvant therapies. In recent years, cell-based therapy and other innovative treatment options have emerged as promising strategies in various medical fields [22][23][24]. Considering the encouraging results in numerous experimental studies, these novel approaches may hold great potential as treatment options for thin endometria.…”

Section: Platelet-rich Plasmamentioning

confidence: 99%

An Update on Experimental Therapeutic Strategies for Thin Endometrium

Tang,

Frisendahl,

Lalitkumar

et al. 2023

Endocrines

View full text Add to dashboard Cite

Infertility caused by a thin endometrium remains a significant challenge in assisted reproduction and is often associated with a low success rate after treatment with assisted reproductive technology. There is a lack of consensus in the field concerning both its diagnostic criteria and clinical management. The currently available treatment options are few with limited efficacy. Recent advances in cell therapy and bioengineering have, however, shown promising results for the treatment of a thin endometrium. Notably, these novel interventions have demonstrated the ability to increase endometrial thickness, restore endometrial function, and improve reproductive outcomes. In this comprehensive review, we focus on a critical evaluation of these emerging therapeutic strategies for a thin endometrium including platelet-rich plasma, exosomes derived from stem cells, and bioengineering-based techniques. By synthesizing the findings from available clinical trials, we highlight the promising outcomes achieved so far and underscore the importance of robust clinical trials in assessing the safety and efficacy of these interventions in the future. Continued research efforts to unravel the intricate mechanisms involved in endometrial repair and regeneration will also be essential to enhance our understanding of this multifactorial condition and to identify novel treatment targets for future therapeutic interventions.

show abstract

Stem Cell Therapy in Neuroimmunologic Diseases

Bose,

Freedman

2024

Reference Module in Neuroscience and Biobehavioral Psychology

View full text Add to dashboard Cite

Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications

Cited by 5 publications

References 182 publications

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

An Update on Experimental Therapeutic Strategies for Thin Endometrium

Stem Cell Therapy in Neuroimmunologic Diseases

Contact Info

Product

Resources

About